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Rotavirus (RV) NSP4, the ﬁrst described viral enterotoxin, is a multifunctional glycoprotein that contributes to viral pathogenesis,
morphogenesis, and replication. NSP4 binds both termini of caveolin-1 and is isolated from caveolae fractions that are rich in
anionic phospholipids and cholesterol. These interactions indicate that cholesterol/caveolin-1 plays a role in NSP4 transport to
the cell surface, which is essential to its enterotoxic activity. Synthetic peptides were utilized to identify target(s) of intervention
by exploring the NSP4-caveolin-1 and -cholesterol interactions. NSP4112−140 that overlaps the caveolin-1 binding domain and
a cholesterol recognition amino acid consensus (CRAC) motif and both termini of caveolin-1 (N-caveolin-12−20, 19−40 and
C-caveolin-1161−180) were synthesized. Direct ﬂuorescence-binding assays were employed to determine binding aﬃnities of the
NSP4-caveolin-1 peptides and cholesterol. Intracellular cholesterol alteration revealed a redistribution of NSP4 and disintegration
of viroplasms. These data further imply interruption of NSP4112−140-N-caveolin-119−40 and cholesterol interactions may block
NSP4 intracellular transport, hence enterotoxicity.
1.Introduction
As the leading cause of gastroenteritis in young children un-
der the age of ﬁve, rotavirus (RV) infections annually are res-
ponsible for approximately 600,000 deaths worldwide [1, 2].
During infection, the RV nonstructural protein 4 (NSP4)
functions as a viral enterotoxin by binding an extracellular
receptor and activating a signal transduction pathway which
increases intracellular calcium ([Ca2+]i) levels through the
release of ER calcium stores [3, 4]. This increase in [Ca2+]i
induces secretory chloride currents which result in diarrhea,
but only when initiated from the exofacial leaﬂet of the
plasma membrane (PM) [3]. The initiated increases in intra-
cellular, calcium levels fail to induce the chloride secretory
response [4–6].
Traditionally deﬁned as an ER glycoprotein, NSP4 con-
tains a single transmembrane domain that serves to anchor
the protein into the ER membrane, such that a short N-
terminal domain (amino acids [aa] 1–24) remains within the
lumen of the ER while the longer C-terminus (aa 45–175)
extends into the cytoplasm [7]. Interactions with numerous
viral and cellular proteins occur within the extended C-
t e r m i n a lt a i lo fN S P 4[ 8–12]. Also contained within the C-
terminal cytoplasmic tail is an amphipathic α-helix (AAH),
coiled-coil domain (aa 95–137) [13, 14]. Cross-linking
and crystallographic experiments reveal that this region of
NSP4 primarily oligomerizes into dimers and tetramers and
contains a cation-binding site [13–15]. Residing within the
amphipathic α-helix, coiled-coil domain is the enterotoxic
peptide region (aa 114–135) as well as the caveolin-1 (cav-1)
binding domain [16] and a putative cholesterol recognition
amino acid consensus (CRAC) sequence [17].
Many cholesterol binding proteins contain a CRAC
sequence characterized by—L/V-(X)(1−5)-Y-(X)(1−5)-R/K-,2 Journal of Amino Acids
where (X)(1−5) represents between one and ﬁve unspeciﬁed
residues [17]. Numerous proteins involved in cholesterol
transport contain this sequence, including cav-1 [18]. How-
ever, the presence of such a sequence does not assure
an interaction with cholesterol, as this sequence is highly
variable and likely is not the only requirement for cholesterol
binding [19]. Yet a number of viral proteins bind cholesterol,
including the HIV-1 gp41 transmembrane glycoprotein [17,
20], the inﬂuenza M2 protein [21], and the F1 subunit of the
fusion protein of Sendai virus [22].
There is compelling evidence that the enterotoxic pep-
tide, NSP4114−135, and the full-length NSP4 protein interact
with cav-1. In vivo laser scanning confocal microscopy
(LSCM) colocalizations, ﬂuorescent energy transfer (FRET)
analyses, and co-immunoprecipitation data from our labo-
ratory verify that NSP4 binds cav-1, the main constituent
proteinofcaveolae,atmultiplesiteswithinthecell,including
the PM [23]. Yeast two-hybrid and in vitro binding assays
conﬁrmaninteractionbetweenNSP4andcav-1andmapthe
cav-1 binding domain to NSP4114−135 [23]. Using deletion
and site-directed mutagenesis, the binding site delineated to
three hydrophobic residues in the enterotoxic region indicat-
ing that NSP4 and cav-1 associate via a hydrophobic interac-
tion (unpublished). Additional studies reveal that the cav-1
binding site for NSP4 maps, to both the N- and C-termini of
cav-1, residues 2–31 and 161–178, respectively [24].
Cav-1 is an intracellular, 21kD protein bound by the
inner leaﬂet of the PM in a hairpin-like structure such that
both the N- and C-termini are oriented towards the cyto-
plasm [23, 25]. Numerous signaling molecules, such as those
involved in calcium signaling, are localized to caveolae and
their function appears to be dependent on interaction with
cav-1 [16, 26, 27]. Cav-1 also binds cholesterol, which has
been shown to be vital to caveolae biogenesis and the trans-
port of cholesterol to caveolae at the PM [28–31].
Puriﬁed NSP4 and NSP4114−135 peptides interact with
caveolae-like model membranes, that is, those that have a
high radius of curvature and are rich in anionic phospho-
lipids and cholesterol [32, 33]. Upon interaction with model
membranes, both the protein and the peptide undergo a
change in secondary structure characterized by an increase
in α-helix formation. Additional secondary structure studies
of other NSP4 peptides that overlap the enterotoxic peptide
and cav-1 binding domain conﬁrm that this region is
important for membrane interactions. When caveolae are
isolated from enriched PM fractions of RV-infected MDCK
cells, the full-length, fully-glycosylated NSP4 is present in
the isolated caveolae fractions verifying transport of NSP4 to
the PM and caveolae [34]. It is possible that the transport of
NSP4 to caveolae occurs through an interaction with cav-1
and cholesterol, although additional studies are needed
to for veriﬁcation. Our studies reveal the exposure of the
NSP4 C-terminus and the enterotoxic region, but not the N-
terminus,ontheouterPMleaﬂetandsubsequentreleaseinto
culturemediaatatimewhenthemembraneisintactasverif-
ied by a lack of exposure of cav-1 and other intracellular
markers [34–36].
In this paper, we have extended these studies using syn-
thetic peptides to address the following questions. (i) Does
NSP4 interact with both termini of cav-1 with equal aﬃnity?
(ii) Do the two termini of cav-1 interact with one another
and thus facilitate binding of NSP4 to both termini? (iii)
Is there a structural change when NSP4 and cav-1 peptides
interact?(iv)DotheoverlappingNSP4-cav-1binding,CRAC
motif, and enterotoxin regions interact with cholesterol?
(v) Does alteration(s) of NSP4-cholesterol binding have a
biological eﬀect? To answer these questions, we employed
peptide-peptide and -cholesterol direct ﬂuorescence-binding
assays to ascertain the interaction and determine the binding
aﬃnities (Kd). We also employed circular dichroism (CD) to
investigate secondary structural changes upon interaction of
thepeptidesintheabsenceorpresenceofmodelmembranes.
2.MaterialsandMethods
2.1. Materials, Antibodies and Cells. Triﬂuoroacetic acid
(TFA), 1-hydroxy-benzotriazole (HOBt), and O-Benzotria-
zole-N,N,N ,N -tetramethyluronium-hexaﬂuoro-phosphate
(HBTU) were purchased from American Bioanalytical (Nat-
ick, MA). N,N-diisopropylethylamine (DIPEA) andN,N -di-
isopropylcarbodiimide (DIPCIDI) were purchased from
CreoSalus (Louisville, KY). Thioanisole, ethanedithiol, and
a n i s o l ew e r ep u r c h a s e df r o mE M Dc h e m i c a l s( G i b b s t o w n ,
NJ).Cholesterol,SephadexG-25,andtriﬂuoroethanol(TFE)
were purchased from Sigma (St. Louis, MO). Phospholipids
DOPS (1,2-dioleoyl-sn-glycero-3-[phosphor-L-serine]) and
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)
were purchased from Avanti Polar Lipids (Alabaster, AL).
Antibodies speciﬁc to the NSP4 peptide aa 150–175
(NSP4150−175; deduced from the simian rotavirus SA11 NSP4
sequence) were generated in rabbits by immunizing with
peptide cross-linked to keyhole limpet hemocyanin as pre-
viously described [23]. Anti-NSP4150−175 was aﬃnity puri-
ﬁed against the inoculating peptide linked to preactivated
cyanogen bromide Sepharose 4B beads according to the
manufacturer (Amersham Pharmacia Biotech, Piscataway,
NJ) [37]. Guinea pig anti-NSP5, a viroplasm (virus factory
in the cell) marker, was a gift from Dr. Oscar Burrone (Inter-
national Center for Genetic Engineering and Biotechnology,
Trieste, Italy). F(ab )2 fragments of goat anti-guinea pig
IgG-Cy3 and goat anti-rabbit IgG-Cy2 were purchased from
Jackson Immuno Research (West Grove, PA).
HT29.f8 cells are a spontaneously polarizing cell line that
was cloned from the human adenocarcinoma HT29 intesti-
nal cell line [38]. Cells were maintained in Dulbecco’s Modi-
ﬁcation of Eagle’s Media (DMEM) with 4.5g/L glucose,
2mM L-glutamine, and 1mM sodium pyruvate (Mediatech,
Inc., Herndon, VA) and supplemented with 5% fetal bovine
sera, 5% Serum supreme, and antibiotics (100u/L penicillin,
100ug/L streptomycin, 0.25ug/L amphotericin B) (Cam-
brex, East Rutherford, NJ). For infection, cells were incu-
bated in the absence of sera exactly as described and exposed
to virus for 1h (multiplicity of infection (MOI) = 2) [23, 35,
36].
2.2. Synthesis and Puriﬁcation of NSP4 and Cav-1 Peptides.
All peptides (Table 1) were synthesized by ﬂuorenylme-
thoxycarbonyl (Fmoc) solid-phase chemistry with eitherJournal of Amino Acids 3
Table 1
Peptide name Peptide sequence (N →C)
NSP4112−140
(aa 112–140)a MIDKLTTREIEQVELLKRIYDKLTVQTTG
NSP4150−175ΔAla QKNVRTLEEWESGKNPYEPREVTAM
N-Cav2−20
(aa 2–20) SGGKYVDSEGHLYTVPIRE
N-Cav19−40
(aa 19–40) REQGNIYKPNNKAMADELSEKQ
Cav68−80
(aa 68–80) FEDVIAEPEGTHS
C-Cav161−178
(aa 161–178) EAVGKIFSNVRINLQKEI
aUnderlined and bold residues indicate the putative CRAC domain.
1-hydroxy-benzotriazole (HOBt), O-Benzotriazole-N,N,N ,
N -tetramethyluronium-hexaﬂuoro-phosphate (HBTU) and
N,N-diisopropylethylamine (DIPEA), or HOBt and N,N -
diisopropylcarbodiimide (DIPCIDI) activation using the
Model 90 Peptide Synthesizer (Advanced Chemtech; Louis-
ville, KY). Following synthesis, the peptides were cleaved
from the solid resin support and all side-chain protecting
groups were removed by the addition of Reagent R (90% tri-
ﬂuoroacetic acid (TFA), 5% thioanisole, 3% ethanedithiol,
and 2% anisole). The peptide/Reagent R cleavage mixture
was incubated at RT for a maximum of 2 hours with gentle
mixing.
To separate the peptides from the solid support, the mix-
ture was ﬁltered through a sintered glass ﬁlter into a 50mL
conicaltubecontainingcolddiethyletherinadryice/ethanol
bath. Following 2-3 rinses of the ﬁlter with TFA, the ether
solution containing the precipitated peptide was centrifuged
at 300g for 4 minutes. The supernatant was removed and
additional cold diethyl ether was added to the peptide pellet.
The mixture was allowed to cool in the dry ice/ethanol bath
for several minutes before repelleting. This step was repeated
an additional two times; the crude peptide was dried under
N2, resolubilized in 10% acetic acid and lyophilized.
Thelyophilizedcrudepeptidewasresuspendedin5–10%
acetic acid and puriﬁed from organic contaminants and
incomplete peptide fragments by gravimetric gel ﬁltration
chromatography (Sephadex G25 medium). The eluted pep-
tide was lyophilized and further puriﬁed by reverse-phase
HPLC using either a reverse phase C4 Delta Pak column
(Waters Chromatography Division, Milford, MA) or a re-
verse phase C18 column (Beckman-Coulter, Fullerton, CA)
depending on the hydrophobicity of the peptide. Eluted
peaks were lyophilized and characterized by matrix-assisted
laser desorption/ionization (MALDI) mass spectrometry
(Laboratory for Biological Mass Spectrometry, Department
of Chemistry, Texas A&M University, College Station, TX).
2.3. Preparation of Small Unilamellar Vesicles (SUV). Small
unilamellar vesicles (SUVs) composed of the neutral lipid
POPC, cholesterol, and the anionic phospholipid DOPS in
the molar ratio 55:35:30 were prepared following a previ-
ously published protocol [33]. This membrane composition
was chosen as a result of previous data showing that this
composition and curvature promote an interaction with
NSP4-speciﬁc peptides as observed by an increase in α-helix
formation [32, 33]. Stock solutions of the lipids dissolved
in chloroform were mixed together in the proper ratio in
an amber glass vial. The solvents were removed under N2
with constant rotation so that the dried lipids formed a thin
ﬁlm on the wall of the glass vial. The vial containing the
dried lipids was further dried under vacuum for a minimum
of 4h. The dried lipids were resuspended in 10mM MOPS
buﬀer, pH 7.4 (ﬁltered through a 0.45μm ﬁlter; Millipore,
Bedford, MA), vortexed and bath sonicated. The resulting
multilamellar membrane suspension was sonicated with a
microprobe under N2 at 4◦C at 2min intervals, followed by
1minpausestopreventoverheatingofthelipidsolution.The
sonicated lipid solution then was centrifuged at 110,000g for
4h to remove any multilamellar vesicles and titanium debris
fromthesonicatorprobe.ThelipidconcentrationoftheSUV
solution was determined by a standard phosphate assay as
described [2]. Brieﬂy, the SUV solutions were mixed with a
10%magnesiumnitrate(Mg(NO3)2)solutionandheatedfor
30min at120◦C.Eachsamplewasashedin aﬂame,600μLo f
0.5N HCl was added, and the samples were heated in boiling
water for 15min. Each sample was mixed with 1400μLo f
a 10% ascorbic acid solution that contained 6 parts of a
0.42% ammonium molybdate solution in 1N sulfuric acid
(H2SO4) and incubated for 20min at 45◦C before reading
the absorbance at 660nm (A660). Lipid concentrations of the
SUVs were determined by comparison to a standard curve of
0–200nmol phosphate.
2.4. Direct Fluorescence-Binding Assays
2.4.1. Direct Peptide-Peptide Interaction. A ﬂuorescence-
binding assay was utilized to investigate direct binding of
the NSP4112−140 peptide with each of the cav-1 peptides (N-
Cav2−20,N - C a v 19−40,C a v 68−80, and C-Cav) [20, 39]. All of
the cav-1 peptides directly were labeled with a Cy3 ﬂuores-
cent dye, using the Cy3 Monoreactive dye pack from Amer-
sham Biosciences according to the manufacturer’s protocol.
Brieﬂy, each peptide was dissolved in 50nM phosphate buf-
fer, pH 7.0, at a concentration of 1mg/mL, and added to a
vial containing lyophilized Cy3 dye. The solution gently was
mixedandincubatedat25◦Cforatleast2hwithintermittent
mixing. Labeled peptides were separated from unlabeled
peptides by Sephadex G25 gel ﬁltration chromatography.
To demonstrate a direct peptide-peptide interaction be-
tween the NSP4112−140 peptide and each of the cav-1 pep-
tides, increasing concentrations of NSP4112−140 (10–500nM)
were added to 25–100nM of the Cy3-labeled cav-1 peptides
in 2mL of phosphate-buﬀered saline (PBS, pH 7.4) in either
the absence or presence of small unilamellar vesicles (SUVs,
1μM). The Cy3 ﬂuorophore was excited at 550nm and
emission spectra were scanned from 560 to 700nm. Fluo-
rescence emission spectra were obtained at 25◦Cw i t haP C 1
photon-counting spectroﬂuorometer with excitation and
emission slit widths of 1.0 (ISS, Inc.). Spectra were corrected
for background and maximal ﬂuorescence intensities were4 Journal of Amino Acids
recorded. Calculation of the dissociation constants (Kd)w a s
performed from the titration curves plotted as quenching in
Cy3-peptide ﬂuorescence intensity (F0 − F,w h e r eF0 and F
represented the Cy3-cav-1 peptide ﬂuorescence intensities in
the absence and presence of NSP4112−140 or cav-1 peptide,
resp., at each titration point) as a function of peptide
concentration. The Kd also was obtained by a reciprocal plot
of 1/(1 − F/Fmax)a n dCL/F/Fmax according to the following
equation: y = bx + y0,w h e r eF is the ﬂuorescence intensity
at a given concentration of ligand, Fmax is the maximal
ﬂuorescence obtained, and CL is the ligand concentration.
The slope of the line (b) is equal to 1/Kd.
2.4.2. Cholesterol-Peptide Interaction. Similarly, the
NSP4112−140-cholesterol interaction and binding aﬃnity
were determined by a direct ﬂuorescent binding assay in
which the peptide was labeled with a Cy5 ﬂuorophore
using the Cy5 Monoreactive dye pack from Amersham Bio-
sciences (Piscataway, NJ). A concentrated cholesterol stock
solution (20uM) was prepared by dissolving the cholesterol
in ethanol. To analyze a binding interaction between
NSP4112−140 and cholesterol, an increasing quantity of chole-
sterol (5–35nM) was added to 10nM of the Cy5-labeled
NSP4112−140 in 2mL of PBS (pH 7.4). The Cy5 ﬂuorophore
wasexcitedatawavelengthof649nm,andtheemissionspec-
tra were scanned from 655 to 720nm using a PCI photon-
countingspectroﬂuorometer(ISS,Inc.,Champaign,IL).Flu-
orescence emission spectra were obtained at 25◦C with exci-
tation and emission slit widths of 1.0. As with the peptide-
peptide interactions, spectra were corrected for background
and maximal ﬂuorescence intensities were measured. Calcu-
lation of the Kd was determined from the plotted titration
curves whereby the Cy5-peptide ﬂuorescence intensity was
quenched and measured as a function of cholesterol concen-
tration (F0 − F,w h e r eF0 and F represented the Cy5-
NSP4112−140 ﬂuorescence intensities in the absence and pre-
sence of cholesterol, resp., at each titration point). The sig-
moidal curves also were ﬁtted to a Hill plot according to the
following equation: y = axb/(cb + xb), where y and x cor-
respond to (F0 − F) and the ligand concentration at each
point, while a, b,a n dc represent the maximum binding
(Bmax), the number of binding sites (n), and the Kd value,
respectively. Kd values were calculated with the sigmoidal
function of Sigma Plot (SPSS, Chicago, IL) utilizing the Hill
plot feature.
2.5.CircularDichroism(CD)andSecondaryStructureEstima-
tions. ThesecondarystructuresoftheNSP4andcav-1speci-
ﬁc peptides were determined by circular dichroism following
apreviouslypublishedprotocol[32,33].Brieﬂy,eachpeptide
(15–35μM) was suspended in 10mM potassium phosphate
buﬀer, pH 7.4, or 50% triﬂuoroethanol (TFE) to promote a
hydrophobic environment and folding of the peptide, in the
presence or absence of lipid vesicles (1mM). Samples con-
taining buﬀer or SUVs without peptide were used for back-
ground correction. Peptide concentrations were determined
by amino acid analysis (Protein Chemistry Laboratory,
Department of Biochemistry, Texas A&M University, College
Station, TX). CD spectra were obtained in a 1mm circular
quartz cell using a Model J-710 JASCO spectropolarimeter
(JASCO, Easton, MD) or in a 1mm rectangular quartz cell in
a Model 202 Aviv spectrometer (Aviv Biomedical, Lakewood,
NJ). The spectra for each of the peptides were recorded from
185nm to 260nm, with a step resolution of 1nm, speed
of 50nm/min, response of 1sec, bandwidth of 2.0nm, and
sensitivity of 10mdeg. Data were averaged from 5 scans,
background subtracted, smoothed, and converted into mean
residue molar ellipticity [θ]( d e gc m 2/dmol).
To determine the percent α-helix for each of the NSP4-
and cav-1 speciﬁc peptides, the following equation was used:
θ222 = (fh − ´ ικ/N)[θh 222∞][ 12, 21, 22]. In this equation,
θ222 is the mean residue molar ellipticity at 222nm, fh is the
fraction in α-helical form, ´ ι is the number of helices, κ is a
wavelength-speciﬁc constant with a value of 2.6 at 222nm,
N is the number of residues in the peptide, and θh 222∞ is the
molar ellipticity for a helix of inﬁnite length at 222nm, that
is, −39,500degcm2/dmol.
2.6. Treatment of RV-Infected MDCK and -HT29.f8 Cells with
Cholesterol-Altering Drugs. MDCK cells were infected with
RV at a multiplicity of infection (MOI) of 2 and incubated
for 12 hpi. The cells were washed and treated in triplicate
with the cholesterol altering drugs, ﬁllipin [40], and nystatin
[41]exactlyasdescribed.Chlorpromazine[40,42]andnoco-
dazole [39] were utilized as negative and positive controls,
respectively. Cells were ﬁxed with methanol:acetone (1:1)
at −20◦C for 10min, blocked with 5% dry milk for 20min,
incubated with anti-NSP4150−175 and anti-rabbit-IgG-FITC,
and examined under a UV microscope (Zeiss). The cell
surface carefully was observed and the presence or absence
of ﬂuorescence carefully noted. Comparisons also were made
to untreated cells. Primary and secondary antibody controls
were negative. To ensure the lack of drug toxicity, a separate
set of cells were treated and then stained with trypan blue.
2.7. Direct Fluorescence-Binding Assays
2.7.1. NSP4112−140 Binds the N-Terminus of cav-1 (Cav19−40)
with Greater Aﬃnity Than the C-Terminus. We previously
demonstrated that NSP4114−135 interacts with both the N-
and C-termini of cav-1 using yeast-2-hybrid and pull-down
assays, which is unusual [24]. To further investigate this ﬁnd-
ing and determine if there was a preferential binding of
NSP4 to the N- or C-terminus of cav-1, the NSP4112−140
peptide that encompasses aa 114–135 and various cav-1 pep-
tides (N-Cav2−20,N - C a v 19−40, and C-Cav161−178)w e r eu t i -
lized in a direct ﬂuorescence-binding assay.
Upon titration with increasing concentrations of
NSP4112−140, each of the Cy-3-labled N- or C-terminal cav-1
peptides showed an increase in ﬂuorescence intensity at
565nm, indicative of an interaction. Plots of NSP4112−140
concentrations versus maximum ﬂuorescence intensities
revealed saturated binding curves for each of the cav-1 pep-
tides (Figure 1). Linear reciprocal plots were used to
calculate the Kd for each peptide-peptide pair (Table 2).
The calculated Kd values indicated that NSP4112−140Journal of Amino Acids 5
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Figure 1: Direct Fluorescence-Binding Assays of NSP4112−140 with Caveolin-1 Peptides. (a) Fluorescence spectra of Cy3-C-Cav161−178 titrated
with increasing concentrations of NSP4112−140. Spectrum 1:100 nM Cy3-C-Cav161−178 in buﬀer only. Spectra 2–11:100nM Cy3-C-Cav161−178
in the presence of 10, 100, 150, 200, 250, 300, 350, 400, 450, and 500 nM of NSP4112−140, respectively. (b) Fluorescence spectra of Cy3-
C-Cav161−178 titrated with increasing concentrations of NSP4150−175 (negative control). Plots (c)–(e) show maximal ﬂuorescence emission
(measured at 565 nm upon excitation at 550nm) for NSP4112−140 in the presence of 25nM Cy3-N-Cav2−20 (c), 50nM Cy3-N- Cav19−40 (d),
and 100 nM Cy3-C-Cav161−178.( e ) .Insets: linear plots of the binding curve of NSP4112−140.6 Journal of Amino Acids
Table 2: Binding aﬃnities (Kd) for NSP4112−140 + caveolin-1
peptides in the absence and presence of SUV model membranesa.
Sample Kd (nM) in
absence of SUV
Kd (nM) in
presence of SUV
Cy3-N-Cav2−20 +
NSP4112−140
85 ±62 6 ±4
Cy3-N-Cav19−40 +
NSP4112−140
40 ±10 37 ±7
Cy3-C-Cav161−178+
NSP4112−140
217 ±35 172 ±22
aThe Kd values were calculated as outlined in Materials and Methods and
are presented as means ± SD, n = 4.
bound the N-Cav19−40 peptide with the strongest aﬃnity
(40 ± 10nM), while it bound the C-Cav161−178 peptide with
the weakest aﬃnity (217 ± 35nM). The N-Cav2−20 peptide
bound with intermediate aﬃnity (85 ± 6nM). None of the
cav-1 peptides bound to the control peptide corresponding
to the C-terminus of NSP4 (NSP4150−175ΔAla), which is
known to not bind cav-1 [23]. It is unusual for a protein
to interact with both termini of cav-1. We now show that
there is a preferential interaction of NSP4112−140 with the
N-terminus of cav-1, which, to our knowledge, is the ﬁrst
report of a preferential binding to one termini of cav-1.
Previous CD analyses of NSP4 peptides corresponding
to the cav-1 binding domain show that aa 114–135 interacts
with model membranes (SUVs) [32, 33]. Therefore, NSP4-
cav-1 peptide-peptide interactions also were investigated in
the presence of the same SUV membranes. The SUVs were
mixedwitheachoftheCy3-labeledcav-1peptidesinPBSand
then titrated with increasing concentrations of NSP4112−140
(Figure 2).
The presence of lipid vesicles had no eﬀect on the inter-
actionofNSP4112−140 witheitherN-Cav19−40 orC-Cav161−178
(Figures 2(b) and 2(c)). Binding aﬃnities in the presence of
membranes were similar to those calculated in the absence
of membranes (Table 2). However, the presence of the SUVs
resulted in an increased aﬃnity between NSP4112−140 and
N-Cav2−20. The calculated Kd value was determined to be
26±4nM,anapproximate3-foldincreaseoverthatobserved
in the absence of membranes (85 ± 6nM) and about a1.5-
fold increase over the Kd of N-Cav19−40 in the absence of
membranes (40 ± 10nM). These results strongly suggest
that the presence of lipid vesicles enhances binding between
NSP4112−140 and the extreme N-terminus of cav-1 (aa 2-20),
but not the adjacent N-terminal cav-1 peptide, N-Cav19−40.
2.7.2. The N-terminal cav-1 Peptides (aa 2–20 and 19–40)
Failed to Bind the cav-1 C-Terminal Peptide (aa 161–178). To
evaluatethemechanismoftheinteractionofNSP4withboth
cav-1 termini, we examined whether the two cav-1 termini
bound one another to facilitate the interaction with NSP4 by
employing the ﬂuorescence-binding assay. C-Cav161−178 was
labeled with a Cy3-ﬂuorophore and titrated with either the
N-Cav2−20 or N-Cav19−40 peptide. Titration of C-Cav161−178
with increasing concentrations of either N-terminal peptide
resulted in no change in ﬂuorescence intensity at 565nm,
Table 3: Percent α-helixa of NSP4112−140and Caveolin-1 Peptides in
Aqueous Buﬀer, 50% TFE and in the Presence of 1mM SUV.
Peptide Aqueous Buﬀer 50% TFE 1mM SUV
NSP4112−140 30.6 ±2.4% 79.6 ±4.6% 57.9 ±1.6%
N-Cav2−20 18.9 ±2.8% 16.5 ±0.9% 18.5 ±1.9%
Cav19−40 20.7 ±0.6% 33.4 ±0.5% 20.5 ±2.7%
Cav68−80 23.4 ±0.9% 24.4 ±0.8% 21.4 ±2.0%
C-Cav161−178 43.4 ±3.8% 57.4 ±4.4% 42.5 ±10.6%
aPercent α-helix for each peptide was calculated as described in Materials
and Methods. Data is presented as mean ± SD, n = 4.
indicative of a lack of association (Figure 3). Hence, we
propose that the N- and C- termini of cav-1 do not bind
one another and the interaction between NSP4 and the cav-
1 termini does not result from an initial binding between
the cav-1 N- and C-termini. To our knowledge, this is the
ﬁrst report of the cav-1 termini not interacting. Additional
studiesareneededtodissectthemechanismandimplications
of both cav-1 termini binding NSP4.
2.8. Circular Dichroism Analysis
2.8.1. Secondary Structure of NSP4112−140. The structure of
the NSP4112−140 peptide was ﬁrst determined in an aqueous
buﬀer (10mM potassium phosphate buﬀer, pH = 7.4)
(Figure 4, dark circles). The CD spectrum showed double
minima at 208 and 222nm and a single maximum peak at
190nm, indicative of some α-helical secondary structure.
Using the molar ellipticity value at 222nm [43], the α-helical
content of the NSP4112−140 peptide was calculated to be
30.6 ±2.4%.
To enhance innate peptide structure, the secondary
structure of NSP4112−140 was determined in 50% TFE, a
hydrophobic solvent that promotes intramolecular hydrogen
bonding (Figure 4, open circles). The CD spectrum showed
ad r a m a t i ci n c r e a s ei nα-helix formation of the peptide,
as evidenced by an increase in both the negative molar
ellipticityat208and222nmandthepositivemolarellipticity
at 190nm. The α-helical content was calculated using the
molarellipticityvalueat222nmanddeterminedtobe79.6±
4.6% (Table 3).
Previous CD experiments with the enterotoxic peptide,
NSP4114−135 demonstrate that the α-helical content increases
in the presence of SUVs containing POPC, cholesterol, and
DOPS at a 55:35:10 molar ratio [32, 33]. To determine the
secondary structural changes that occur in the presence of
membranes, NSP4112−140 was mixed with SUV membranes
and changes in α-helical content were noted by CD.
The CD spectrum of the NSP4112−140 peptide in the
presence of 1mM SUV showed nearly a 2-fold increase in
α-helix formation over that in aqueous buﬀer, as evidenced
by the increase in both the negative molar ellipticity as 208
and 222nm and the positive molar ellipticity at 190nm
(Figure 5). The α-helical content was calculated using the
molar ellipticity value at 222nm and determined to be
57.9 ±1.6% (Table 3).Journal of Amino Acids 7
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Figure 2: Direct Fluorescence-Binding Assays of NSP4112−140 with Caveolin-1 Peptides in the presence of 1μM SUV model membranes.
Direct binding based on dequenching of Cy3 ﬂuorescence emission. (a–c) Plots of maximal ﬂuorescence emission (measured at 565nm
upon excitation at 550nm) for NSP4112−140 in the presence of 1uM SUV and either 25nM Cy3-N-Cav2−20 (a), 50nM Cy3-Cav19−40 (b), or
100nM Cy3-C-Cav161−178 (c). Insets: linear plots of the binding curve of NSP4112−140.
2.8.2. Secondary Structure of Caveolin-1 Peptides. The sec-
ondary structures of the cav-1 peptides were determined
and evaluated in the presence of 50% TFE and 1mM SUVs
(55:35:10; POPC:Cholesterol:DOPS) by CD (Table 3).
In aqueous buﬀer, the α-helical content of N-Cav2−20,N -
Cav19−40,a n dC a v 68−80 was quite similar, at 18.9%, 20.7%,
and 23.4%, respectively (Figures 6(a)–6(c),d a rkc i r c l e s ) .T h e
α-helical contents of the C-terminal peptide (C-Cav161−178)
was approximately twice (43.4%) that of the N-terminal
peptides (Table 3). When placed in 50% TFE, the α-
helical content of N-Cav2−20,N - C a v 19−40,C a v 68−80, and C-
Cav161−178 peptides were calculated to be 16.5%, 33.4%,
23.1%, and 67.1% respectively (Figure 6,o p e nc i r c l e s ) .O n l y
N-Cav19−40 and C-Cav161−178 showed an increase in α-helix
formation in the presence of 50% TFE.
When mixed with the SUVs, none of the cav-1 peptides
demonstrated a change in α-helix formation over that seen
in aqueous buﬀer (Figure 6, dark triangles). This result was
anticipatedasnoneofthesepeptidescorrespondedtoacav-1
membrane interacting or transmembrane domain.
2.8.3. Secondary Structural Changes Observed upon Mix-
ing NSP4112−140 with C-Cav161−178. Analyses by direct
ﬂuorescence-binding assays revealed that N-Cav19−40 bound
NSP4112−140 with a stronger aﬃnity than C-Cav161−178.W e
therefore investigated whether structural changes occurred
upon the association of the NSP4 and cav-1 peptides, in par-
ticular with the amino terminus. Each of the cav-1 peptides
(N-Cav2−20,N - C a v 19−40,C a v 68−80, and C-Cav161−178)w a s
mixedwiththeNSP4112−140 peptideandwasanalyzedbyCD.
Cav68−80 was used as a negative control, as previous studies
have shown that NSP4 does not interact with this region
of cav-1 [23, 24]. Analyses of the mixing experiments were
achievedbycomparingthespectrumofeachpeptide-peptide
mixture (observed) with the sum of the individual spectra8 Journal of Amino Acids
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Figure 3: Direct Fluorescence-Binding Assays of N-Cav2−20 or N-Cav19−40 Peptide with C-Cav161−178 Peptide. (a) Fluorescence spectra of
Cy3-C-Cav161−178 titrated with increasing concentrations of Cav19−40 (0–500nM). (b-c) Plots of maximal ﬂuorescence emission (measured
at 565nm upon excitation at 550nm) for (b) N-Cav2−20 and (c) N-Cav19−40 in the presence of 100nM Cy3-C-Cav161−178. Insets: linear plots
of the binding curve of (b) N-Cav2−20 and (c) N-Cav19−40.
of each peptide (theoretical). The α-helical content was
calculated and signiﬁcant diﬀerences (Student’s t-test, P<
0.05) between the observed and theoretical values indicated
achangeinsecondarystructureandbindingbetweenthetwo
peptides. However, a lack of secondary structural alterations
upon mixing the peptides did not negate binding between
the NSP4112−140 and the cav-1 peptide being tested. While
direct ﬂuorescent binding assays revealed the aﬃnity of each
of the peptide-peptide interactions, the CD experiments
disclosed the extent to which the interaction(s) caused a
change in the secondary structure.
When each of the cav-1 peptides was mixed with
NSP4112−140 in an aqueous buﬀer, only the NSP4112−140-C-
Cav161−178 mixture showed a signiﬁcant diﬀerence between
the observed and theoretical values (25.0 ± 1.7% versus
35.3 ± 1.6% α-helix) (Figure 7(d); Table 4). No change in
secondary structure was observed for the NSP4112−140-N-
Cav2−20 (21.7±0.8%versus23.6±2.6%),theNSP4112−140-N-
Cav19−40 (23.8±1.2%versus24.4±0.6%),ortheNSP4112−140-
Cav68−80 negative control (24.2 ± 0.3% versus 23.9 ± 0.7%)
mixtures even though N-Cav19−40 had the lowest Kd (Figures
7(a)–7(c); Table 4). Similarly, when each peptide-peptide
pair was placed in 50% TFE, only the NSP4112−140-C-
Cav161−178 mixture showed a signiﬁcant change in secondary
structure (44.2±10.6% versus 67.8±3.2%) (Table 4). These
data conﬁrmed the weak binding between NSP4112−140 and
C-Cav161−178 and veriﬁed that secondary structure alter-
ations do not always occur upon an interaction.
2.9. Eﬀect of SUV Model Membranes on the NSP4112−140-
Caveolin-1 Peptide-Peptide Interactions. C a v - 1i sc r i t i c a lt o
both the structure and function of caveolae, is the major
constituent of caveolae, and is controller of caveolae for-
mation [44]. NSP4 is present in isolated caveolae from RV-
infected cells [34], and together with NSP4114−135,p r e f e r -
entially interacts with caveolae-like model membranes [32].
Therefore we evaluated the extent the SUVs inﬂuenced
secondary structure alterations of the NSP4-cav-1 peptide-
peptide interactions. Each NSP4112−140-cav-1 peptide pair
was monitored by CD (Figure 8).Journal of Amino Acids 9
Table 4: Observed and theoretical % helical content of NSP4112−140-caveolin-1 peptide-peptide interactions.
N-Cav2−20 Cav19−40 Cav68−80 C-Cav161−178
Observed Theoretical Observed Theoretical Observed Theoretical Observed Theoretical
Aqueous buﬀer 21.7 ±0.82 3 .6 ±2.62 3 .8 ±1.22 4 .4 ±0.62 4 .2 ±0.32 3 .9 ±0.72 5 .0 ±1.7∗ 35.3 ±1.6
50% TFE 46.3 ±7.24 7 .6 ±1.85 8 .7 ±7.75 6 .3 ±2.34 5 .9 ±2.84 9 .8 ±1.84 4 .2 ±10.6∗ 67.8 ±3.2
1mMSUV 34.7 ±6.03 7 .7 ±1.93 7 .7 ±3.63 9 .0 ±2.33 1 .3 ±0.2∗ 37.5 ±1.95 1 .9 ±2.44 9 .5 ±6.2
NSP4112−140-Caveolin-1 Peptide-Peptide Interactions: Percent α-helical content of NSP4112−140 peptide + Caveolin-1 peptides, in aqueous buﬀer (10mM
potassium phosphate buﬀer), 50% triﬂuoroethanol (TFE) and in the presence of 1mM SUV (55:35:10, POPC/cholesterol/DOPS). Observed values were
compared with theoretical values, and those that were statistically signiﬁcant by a Student’s t-test (P<0.05; denoted by an asterisk) were considered
structurally altered, indicative of an interaction. Results are presented as means ± S.D. (n = 3o r4 ) .
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Figure 4: CD spectra of NSP4112−140 in aqueous buﬀer (•) and 50%
TFE (◦).
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Figure 5: CD spectra of NSP4112−140 in aqueous buﬀer (•)a n d
in the presence of 1mM SUV model membranes (55:35:10,
POPC/cholesterol/DOPS) (◦).
Even though the NSP4112−140-C-Cav161−178 peptide pair
showed the most change in α-helical content in aqueous
buﬀer and 50% TFE, in the presence of SUVs there was
not a signiﬁcant conformational change indicating that this
interaction was not enhanced by the presence of model
membranes (Table 4). Similarly, the NSP4112−140-N-Cav19−40
showed the strongest aﬃnity by direct ﬂuorescent binding
assays (Table 2), yet this interaction failed to result in a
signiﬁcant change in secondary structure when mixed with
membranes. The observed α-helical content did not vary
fromtheexpectedtheoreticalvalue,regardlessofwhetherthe
peptide mixture was in aqueous buﬀer, 50% TFE, or mixed
with SUVs. These results suggest that the strong binding
between NSP4112−140 and N-Cav19−40 required neither a
change in structure nor the presence of speciﬁc lipids.
Only the NSP4112−140-Cav68−80 (negative control) mix
ture showed a signiﬁcant change in the α-helical content in
the presence of the SUVs (31.3 ± 0.2% versus 37.5 ± 1.9%)
(Figure 8(c); Table 4). It is currently unclear why the control
peptide mixture resulted in an alteration in helical structure
and requires further study.
2.10. NSP4112−140 Peptide-Cholesterol Interaction. The
NSP4112−140 peptide, which contains the CRAC motif,
was labeled with a Cy5-ﬂuorophore and titrated with cho-
lesterolinadirectﬂuorescence-bindingassay.Themaximum
solubilityofcholesterolinwateris4.7μMandthecriticalmi-
cellar concentration (CMC) is 25–40nM [18], so cholesterol
concentrations were kept below these limits in the binding
assays.
In the absence of cholesterol, the Cy5-NSP4112−140 pep
tide showed maximum ﬂuorescence at 665nm (Figure 9).
Upon titration with increasing concentrations of cholesterol
(5–35nM), Cy5-NSP4112−140 showed a decrease in ﬂuores-
cence intensity, indicative of an interaction. Measurements
of ﬂuorescent intensities at 665nm of Cy5-NSP4112−140 in
the presence of increasing concentrations of cholesterol
were corrected for background (Cy5-NSP4112−140 in buﬀer
alone)andplottedasafunctionofcholesterolconcentration,
demonstrating a saturable binding curve (Figure 9(b)). The
Kd of cholesterol for NSP4112−140 was calculated to be 8 ±
1nM. A Hill plot revealed a single cholesterol binding site
(n = 1) in the 28 residue peptide. A control peptide
(NSP4150−175ΔAla), corresponding to the C-terminus of NSP410 Journal of Amino Acids
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Figure 6: CD Spectra of cav-1 peptides in aqueous buﬀer (•), 50% TFE (◦), and in the presence of 1mM SUV (55:35:10,
POPC/cholesterol/DOPS) (). (a) N-Cav2−20;( b )N - C a v 19−40;( c )C a v 68−80; (d) C-Cav161−178.
and lacking the CRAC motif, failed to demonstrate a change
in ﬂuorescence intensity in the presence of cholesterol,
indicative of a lack of binding (Figures 9(c) and 9(d)).
2.11. Cholesterol Altering Drugs Disrupt NSP4 Transport.
Speciﬁc inhibitors aid in the dissection of biological pro-
cesses. We evaluated the eﬀect(s) of drugs known to disrupt
cholesterol (ﬁllipin, nystatin, lovastatin) [40, 41, 45], hence
caveolin/caveolae transport properties [46], an inhibitor of
clathrin-coated pit processes (chloropromazine) [40, 42],
and a disruptor of the cytoskeleton (nocodazole) [39]. Cells
were treated at the recommended eﬀective dose, evaluated
with trypan blue to ensure a lack of toxicity, and NSP4 trans-
port to the cell periphery was noted. Whenever cholesterol
traﬃckingwasdisrupted,NSP4likewisefailedtotransportto
the cell surface as evidenced by a lack of peripheral staining
(Table 5).
3. Discussion
Several reports highlight the use of peptides as a means of
investigating the interactions of full-length proteins [3, 47–
50].Thisstudysimilarlydemonstratedtheutilityofsynthetic
peptides by showing diﬀerential binding of NSP4112−140
to the cav-1 termini and disclosing secondary structural
changes that were not necessary for the interaction between
the NSP4 and cav-1 binding domains. We also demonstrated
a direct interaction between NSP4 and cholesterol. The Kd
was calculated as 8.0 ± 1nM and a Hill plot revealed a single
binding site for cholesterol when reacted with NSP4112−140.
An interaction between NSP4114−135 and the cellular
protein cav-1 [23–25] as well as caveolae is well estab-
lished [34]. Additionally, we report the interaction of NSP4
with both the N- and C-termini of cav-1 (aa 2–31 and
161–178, resp.) based on yeast two-hybrid analyses andJournal of Amino Acids 11
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Figure 7: CD spectra of NSP4112−140-caveolin-1 peptide-peptide interactions in aqueous buﬀer. (a) NSP4112−140 +N - C a v 2−20;( b )
NSP4112−140 +C a v 19−40; (c) NSP4112−140 +C a v 68−80; (d) NSP4112−140 +C - C a v 161−178.( •) NSP4112−140 spectra; (◦)-Cav-1 peptide spectra;
() Theoretical spectra; (Δ) Observed spectra peptide-peptide combination was mixed with the SUVs, and any alteration in structure was
noted.
Table 5: Treatment with cholesterol-altering drugsa.
Inhibitor Action Results
Fillipin Cholesterol-binding; disrupts caveolae and caveolar membrane transport. Disrupted NSP4 transport
Nystatin Cholesterol-binding; disrupts caveolae and caveolar membrane transport. Disrupted NSP4 transport
Chlorpromazine Inhibits clathrin-dependent endocytosis and coated pit processes. Normal NSP4 transport to the PM.
Nocodazole Disrupts microtubule polymerization Disrupted NSP4 transport
aEach inhibitor was reacted with RV-infected MDCK cells. The cells were washed, stained for NSP4 (anti-NSP4150−175) and a ﬂuorescent secondary antibody
(rabbit anti-IgG-FITC), and the intracellular location compared to untreated, infected cells. Chlorpromazine and nocodazole were included as controls.
in vitro peptide binding assays [24]. Herein, we conﬁrmed
the interaction between NSP4 and the N- and C-termini
of cav-1 and calculated the binding aﬃnities of those
interactions using peptides and direct ﬂuorescence-binding
assays. NSP4112−140, which encompasses the cav-1 binding
domain and overlaps the AAH and enterotoxic peptide,
was utilized with cav-1 peptides corresponding to the N-
(N-Cav2−20 and N-Cav19−40) and C- (C-Cav161−178) termini
and a central region (Cav68−80). Calculations of the binding
aﬃnities revealed that NSP4112−140 bound the N-terminus12 Journal of Amino Acids
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Figure8:CDspectraofNSP4112−140-Cav-1peptide-peptideinteractionsinthepresenceof1mMSUV(55:35:10,POPC/cholesterol/DOPS)
in aqueous buﬀer. (a) NSP4112−140 +N - C a v 2−20; (b) NSP4112−140 +C a v 19−40; (c) NSP4112−140 +C a v 68−80; (d) NSP4112−140 +C - C a v 161−178.( •)
NSP4112−140 spectra; (◦) Cav-1 peptide spectra; () Theoretical spectra; (Δ)-Observed spectra.
of cav-1 (N-cav19−40)w i t ha na ﬃnity over 5 times stronger
than that of the C-terminus (C-cav161−178)( 4 0± 10nM
versus 217 ± 35nM, resp.). When mixed with SUVs, the
Kd values showed an increase in binding aﬃnity for the
NSP4112−140-N-Cav2−20 interaction such that this peptide-
peptideinteractionoccurredwithsimilaraﬃnity(26±4nM)
as that observed between NSP4112−140 and N-Cav19−40 in the
absence of membranes (40 ± 10nM). No change, however,
was observed in the binding aﬃnities between NSP4112−140
and N-Cav19−40 or C-Cav161−178 in the presence of the lipid
vesicles indicating that lipids were not involved in these
interactions. The functional signiﬁcance of the preferential
binding to N-terminal cav-1 currently is unknown.
While we did not speciﬁcally analyze the oligomerization
of the NSP4112−140 peptide in this study, our previous data
on a similar and overlapping peptide (NSP4114−135) showed
oligomerization/aggregation at a peptide concentration of
∼50uM [32]. The peptide concentration utilized in the
binding assays stayed within the nM range, well below the
50uM concentration at which the oligomerization occurred
with the NSP4114−135 peptide.
Following conﬁrmation of an interaction between NSP4
and both termini of cav-1, we analyzed potential secondary
structural changes upon peptide-peptide association by CD.
Previous secondary structure analysis of NSP4114−135 yielded
an estimate of 37% α-helix for the peptide [32, 33]. Analyses
of the secondary structure of the full-length NSP4 protein
showed ∼26% α-helix when analyzed by CD [32]. To our
knowledge, all other structural studies of NSP4 were com-
pleted on speciﬁc fragments of NSP4 and not the full-lengthJournal of Amino Acids 13
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Figure 9:CholesteroldirectlybindsNSP4112−140 peptide.(a)FluorescencespectraofCy5-NSP4112−140 titratedwithincreasingconcentrations
of cholesterol. Spectrum 1:10nM Cy5-NSP4112−140 in buﬀer only. Spectra 2–8:10nM Cy5-NSP4112−140 in the presence of 5, 10, 15,
20, 25, 20 and 35nM of cholesterol, respectively. (b) Plot of maximal ﬂuorescence emission (measured at 665nm upon excitation at
649nm) for cholesterol in the presence of 10nM Cy5-NSP4112−140. Values represent the mean ± S.E., n = 4. (c) Fluorescence spectra of
Cy5-NSP4150−175ΔAla (negative control) titrated with increasing concentrations of cholesterol. (d) Plot of maximal ﬂuorescence emission
(measured at 665nm upon excitation at 649nm) for cholesterol in the presence of 10nM Cy5-NSP4150−175ΔAla. Values represent the mean ±
S.E., n = 4.
protein. The C-terminal region of NSP4 clearly is helical
[13]. CD analysis of NSP4112−140 showed 30% α-helix, which
is within the range calculated for the enterotoxic peptide
and the full-length protein. When placed in the presence of
SUVs, which mimics the more biologically relevant caveolae
environment, NSP4112−140 demonstrated an increase in α-
helical content. This increase in α-helix formation indicated
thatthispeptidebehavedsimilarlytotheNSP4114−135 peptide
and the presence of membranes inﬂuenced the structure.
To date the crystallographic structure of cav-1 has not
been resolved; however, limited secondary structural studies
and bioinformatics analyses have provided insight into
its folded conformation. CD analysis of aa 1–101 reveals
that the N-terminus contains 20% α-helix, with aa 79–96
constituting the α-helix portion, while aa 1–78 likely lacks
signiﬁcant secondary structure [51]. An additional study,
which used a bioinformatics approach, notes that aa 95–101
contains α-helical structure, while aa 84–94 forms two β-
strands [52]. Further, cav-1 is known to form high molecular
weight oligomers that requires the cav-1 scaﬀolding domain
(CSD, aa 82–101) [52–54]. Additionally, the C-terminus is
palmitoylatedonthreecysteines,whichhelpsanchorthepro-
tein to the membrane and may thus explain the preferential
binding of NSP4 to the N-terminus of cav-1 [54–56].
The data presented herein expand on the currently
reported structural information of cav-1. Peptides corre-
sponding to the N-terminus of cav-1 displayed ∼20% α-
helix, whereas the cav-1 C-terminal peptide unexpectedly
showed 43% α-helix, twice that of the N-terminus when
peptides were analyzed by CD. This was surprising as the
bioinformatics study predicted that the C-terminus would
contain primarily random secondary structure. Hence, our
data show that the cav-1 C-terminus contains helical struc-
ture, suggesting that it may not exclusively be random, and14 Journal of Amino Acids
supports the consensus structural predictions of cav-1 aa
134–167 [52].
CD analysis of NSP4-cav-1 peptide-peptide interactions
revealed that there was no signiﬁcant change in α-helix
formation upon binding of NSP4112−140 and the N-Cav19−40
peptide. However, a structural change was noted upon inter-
action of NSP4112−140 with N-Cav2−20 and C-Cav161−178.
Taken together with the binding assays, these results reveal
that while the interaction between NSP4112−140 and N-
Cav19−40 occurs with a strong aﬃnity, binding does not re-
quire a conformational change. However, the secondary
structure change observed when the NSP4112−140 and C-
Cav161−178 peptides were mixed likely occurred to allow the
two peptides to interact, albeit more weakly.
A statistically signiﬁcant conformational change was ob-
served when the NSP4112−140-Cav68−80 mixture was com-
bined with model membranes. Since cav-168−80 is located
near the N-terminal membrane attachment domain (N-
MAD; aa 82–101), as well as the transmembrane domain (aa
102–134) of cav-1, it was postulated that the observed con-
formational change was due to the interaction of Cav68−80
with the lipid vesicles. However, when Cav68−80 was mixed
with SUVs in the absence of NSP4112−140, no change in sec-
ondary structure was observed. Extensive studies are needed
todissecthowtheSUVsalterthestructureoftheNSP4112−140
and Cav68−80 mixture.
The interaction of NSP4 with both termini of cav-1 is
unique, as most cav-1 binding proteins interact with the
CSD [57, 58]. Since NSP4 (aa 112–140) interacted with the
N-terminus of cav-1 more strongly than the C-terminus,
it is possible that the interaction with the C-terminus is
transitory. NSP4 activates signaling pathways that mobilize
[Ca2+]i, requiring the protein to interact with membrane-
associated signaling molecules [59, 60]. The weak binding
between NSP4 and the C-terminus of cav-1 may serve to
present and/or orient the viral protein for interactions with
signaling molecules or lipids, such as the phosphoinositides.
Once NSP4 is properly presented to signaling molecules
withinthemembrane,theC-terminusofcav-1maythenqui-
ckly disassociate thus allowing NSP4 to carry out its biolog-
ical function(s). Since the C-terminus of the cav-1 protein
is closely associated with membranes and does not extend
into the cytoplasm to the same extent as the N-terminus,
it likely has less ﬂexibility and/or accessibility for interac-
tions with other proteins. This lack of freedom is another
potentialexplanationfortheweakbindingobservedbetween
NSP4 and the C-terminus of cav-1.
IthasbeenshownthatNSP4isreleasedfromRV-infected
cells in diﬀerent forms dependent on the cell type, virus
strain, and MOI [36, 61, 62]. The diﬀerential binding of
NSP4 to the N- and C-termini of cav-1 could also contribute
to the presentation and transport of NSP4 across the PM
and provide a key target to block NSP4 from exiting the cell.
Many models can be envisioned to explain how NSP4 inter-
acts with both cav-1 termini. Results of the ﬂuorescence-
binding assay showed that the N- and C-termini of cav-1 do
not interact, so this possibility can be ruled out. It is likely
that diﬀerent molecules of NSP4 associate with the indivi-
dual cav-1 termini.
Lastly, we demonstrated that an RV NSP4 peptide
directly interacted with cholesterol and this interaction
overlapped the amphipathic α-helix, the enterotoxic peptide,
and cav-1 binding domains (aa 112–140), as well as a puta-
tive CRAC motif. The interaction between cholesterol and
theNSP4CRACsequencehasimplicationsforthetraﬃcking
ofNSP4inRV-infectedcells.Giventhatcaveolaeareinvolved
in de novo cholesterol transport from the ER to PM caveolae
[30, 39] and cav-1 assists in cholesterol transport [29, 30,
63, 64], contains a CRAC motif, and binds cholesterol in a
1:1 ratio, it is reasonable to propose that cav-1 and cho-
lesterolfunctioninNSP4intracellularlocalizationandtrans-
port [65, 66]. Indeed the interaction between NSP4 and
cholesterol supports the hypothesis that NSP4 traﬃcs via a
cholesterol transport pathway in RV-infected cells. Likewise,
NSP4 interacts with cav-1, has a proposed CRAC motif, traf-
ﬁcs to the cell surface via a Golgi-bypassing, unconventional
pathway [7, 34, 36, 67], and, as we show herein, interacts
w i t hc h o l e s t e r o lw i t haKd of 8 ± 1nM. We also showed
that the NSP4-cholesterol interaction was speciﬁc to aa 112–
140, as there was no binding to a C-terminal NSP4150−175ΔAla
peptide.
Based on these results using synthetic peptides, we hypo-
thesize that NSP4 traﬃcs with cholesterol and cav-1 from
the ER to the PM, and to viroplasms via association to cho-
lesterol. Additional studies are needed to verify this hypothe-
sis, dissect NSP4 transport to the PM, and resolve viroplasm
localization, all of which may constitute novel targets of
reducing NSP4 eﬀects.
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